What does this research mean for the field?

Optimized 1-methyl-3-(pyridin-3-yl)-1H-indol derivatives act as selective ROR1 inhibitors with improved activity and pharmacokinetic profiles. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

June 2, 2025

View Full Paper

Optimization of 1-Methyl-3-(pyridin-3-yl)-1H-indol Derivatives as ROR1 Inhibitors with Improved Activity and Selectivity

Key Points

Key points are not available for this paper at this time.

Abstract

, and an optimized PK profile, marking a substantive advance toward selective ROR1 inhibitors.

Ask AI

Helpful

Bookmark

View Full Paper

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Zheng et al. (Mon,) studied this question.

synapsesocial.com/papers/6a0774b402b4a6d6a3d3faf3 https://doi.org/https://doi.org/10.1021/acs.jmedchem.5c00189

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1NKX2-1/TITF1/TTF-1-Induced ROR1 Is Required to Sustain EGFR Survival Signaling in Lung Adenocarcinoma2012 · 250 citations
2Preclinical development of novel humanised ROR1 targeting chimeric antigen receptor T cells and bispecific T-cell engagers2017 · 7 citations
3Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia2018 · 188 citations
4NBE-002: A novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors—A phase 1/2 clinical trial.2021 · 25 citations
5Ror1 Is a Pseudokinase That Is Crucial for Met-Driven Tumorigenesis2011 · 138 citations